E-Mail
(Philadelphia, PA) - About 6.2 million Americans suffer from heart failure, an incurable disease with a staggering mortality rate - some 40 percent of patients die within five years of diagnosis. Heart failure is one form of heart disease, for which new therapies are desperately needed.
Now, in new work, scientists at the Lewis Katz School of Medicine (LKSOM) at Temple University identify a path to a promising novel therapeutic strategy, taking aim at a molecule in the heart known as G protein-coupled receptor kinase 5 (GRK5). In a study published online in the journal
Cardiovascular Research, the scientists show in mice that reducing GRK5 levels can significantly improve survival following heart attack.